Eyebot
PrivateLast Round
Series A
Aug 26, 2025
Total Funding Raised
$27.25M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Eyebot operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in August 2025.
Eyebot is a healthcare technology company that develops automated, self-serve vision testing kiosks designed to provide accessible eye prescriptions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Retail Technology, Telemedicine
Business Model
B2B2C
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eyebot Comparables
Compare Eyebot with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GlobeChek | 78% | |
| Visibly | 78% | |
| DigitalOptometrics | 78% |
For institutional investors. Book with your work email.
Eyebot Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 26, 2025 | ||||
| Seed | Jun 6, 2024 | ||||
| Pre Seed | Sep 29, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Eyebot Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AlleyCorp | Series A, Seed |
| Ravelin Capital | Seed |
| General Catalyst | Series A |
| Village Global | Seed, Series A |
| Village Global | Seed, Pre Seed, Series A |
| Humba Ventures | Seed, Series A |
| Spacecadet Ventures | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors grew 39% MoM, reaching 11.3K.
- Feb 3, 2026
Automated vision testing technology pilot program launching December 1st, 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesAug 20, 2026
On Aug '26, Eyebot launches its automated vision test kiosk in select QUAY retail stores in California, enabling customers to receive doctor-verified eyeglass prescriptions in less than 15 minutes while shopping for new glasses.
- partners_withAug 20, 2026
On Aug 20th '26, Eyebot and Quay partner to make automated vision test kiosks available in select Quay retail stores in California, allowing customers to obtain doctor-verified prescriptions while shopping for eyewear.
For institutional investors. Book with your work email.
Eyebot Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Eyebot's valuation, stock price, and market status.
Is Eyebot a public or private company?
Eyebot is a private company.
What is the current stock price of Eyebot?
Eyebot is a private company, so its shares have no public market price. Caplight tracks Eyebot's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eyebot worth (valuation)?
Valuation information for Eyebot is not publicly available.
Can I buy Eyebot stock?
Eyebot shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eyebot's last funding round?
Eyebot's most recent funding round was Series A on August 26, 2025.
Who are the main investors in Eyebot?
Key investors in Eyebot include AlleyCorp, General Catalyst, Ubiquity Ventures.
Will Eyebot IPO soon?
No public IPO plans have been announced for Eyebot.
How can I track Eyebot secondary market activity?
Caplight tracks bids, offers, and trades in Eyebot's shares on secondary markets.